Mineralys Therapeutics, Inc. (MLYS) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Mineralis Therapeutics (MLYS) Q1 2026: R&D Spend Falls 36% as Larundrastat Enters NDA Countdown
May 07, 2026
-
Mineralis Therapeutics (MLYS) Q4 2025: R&D Spend Drops 22% as NDA Acceptance Sets Up PDUFA Catalyst
March 13, 2026
-
Mineralis (MLYS) Q3 2025: $395M Cash Surge Extends Runway Into 2028 as NDA Nears
November 11, 2025
-
Mineralis (MLYS) Q2 2025: $324.9M Cash Position Extends Runway Beyond Pivotal Lorundrastat Milestones
August 12, 2025
-
Mineralis (MLYS) Q1 2025: $201M Raise Extends Runway as Lorundrastat Moves Toward NDA
July 07, 2025